Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 285 → 330 participants Show 5 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 1 of 9 entries
    • Study description expanded, about 7 words
    • Site contacts updated at 1 of 6 sites
    • Publications: details revised at 1 of 1 entry
  2. Enrollment target: 115 to 285
    • Eligibility criteria expanded, about 8 words
    • Site contacts updated at 6 of 6 sites
    v7
  3. Study sites: 5 to 6v6
  4. Study sites: 4 to 5v5
  5. Study sites: 2 to 4v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 1 to 2v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2024 to Jun 12, 2024
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ModeX Therapeutics, An OPKO Health Company
4 trials monitored
See all monitored trials
Breast Cancer
5,455 trials monitored
See 306 trials at risk
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
and 15 more diseases
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Trial Details
NCT Number NCT06239194
Lead Sponsor ModeX Therapeutics, An OPKO Health Company
Conditions
(from sponsor)		 Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer +13 more
Related terms Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Cholangiocarcinoma, Colonic Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Cervical Neoplasms
Enrollment 330 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov